Sirona Biochem
950-789 West Pender Street
Vancouver
British Columbia
V6C 1H2
Canada
Tel: 604-641-4466
Fax: 604-608-5471
Website: http://www.sironabiochem.com/
Email: info@sironabiochem.com
114 articles about Sirona Biochem
-
Sirona Biochem Announces Close of Private Placement
4/5/2024
Sirona Biochem Corp. has closed its private placement for gross proceeds of $132,500 CAD.
-
Sirona Biochem Announces 2023 Annual Meeting Results
3/28/2024
Sirona Biochem Corp. announces the voting results from its Annual General Meeting of Shareholders, held in Vancouver, British Columbia on March 28, 2024.
-
Sirona Biochem Receives Commercial-Grade GlycoProteMim Based Anti-Aging Serum Formulations
3/13/2024
Sirona Biochem Corp announces a significant achievement in its quest to transform the skincare industry.
-
Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025
2/21/2024
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey.
-
Sirona Biochem Provides Update on Loan - February 15, 2024
2/15/2024
Sirona Biochem Corp. announce that, further to its news release on January 29, 2024, it has entered into an amendment to the demand grid promissory note dated September 22, 2023 with 0906462 B.C. Ltd.
-
Sirona Biochem Engages Global Beauty Consulting
2/15/2024
Sirona Biochem Corp. has announced its partnership with Global Beauty Consulting – Cosmetics Laboratory, under the leadership of CEO Gaël Boutry, a distinguished French formulator.
-
Sirona Biochem Announces Loan
1/29/2024
Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ” or the “ Company ”) announced that it has entered into a demand grid promissory note (the “ Note ”) with 0906462 B.C. Ltd. (the “ Lender ”) for a loan in the aggregate principal amount of up to $1,000,000 (the “ Loan ”).
-
Sirona Biochem Initiates Private Placement
1/26/2024
Sirona Biochem Corp. is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.10 CAD per Unit for gross proceeds of up to CAD$1,000,000.
-
Sirona Biochem Corporate Update January 2024
1/24/2024
We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.
-
CORRECTION -- Sirona Biochem Corporate Update January 2024
1/24/2024
We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem's path forward.
-
Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326
12/11/2023
Sirona Biochem Corp., is making a strategic move in the world of advanced skincare solutions.
-
Sirona Biochem Announces Change of Auditor
10/25/2023
Sirona Biochem Corp. announces that it has changed its auditors from DeVisser Gray LLP Davidson and Company effective October 25, 2023 and the board of directors of the Company appointed the Successor Auditor as the Company’s auditor effective October 25, 2023 until the next Annual General Meeting of the Company.
-
Sirona Biochem Corporate Update - July 13, 2023
7/13/2023
Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“ Sirona ”) provides the following update: Dear shareholders, We are pleased to provide an update on the progress we have made over the last months: Corporate Strategic Planning One of our communicated objectives in 2022 and the first half of 2023 was to conduct a thorough strategic review of the company.
-
Sirona Biochem Advances Antiviral Research with New Compound Candidates for Testing at the ICGEB
6/28/2023
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is excited to announce the development of a promising new set of potential antiviral compounds which will undergo testing at the renowned International Centre for Genetic Engineering and Biotechnology ( ICGEB ).
-
Sirona Biochem Engages Atheln Inc. to Strengthen Business Development Initiatives
5/25/2023
Sirona Biochem Corp. is pleased to announce it has contracted Atheln Inc., a leading US consulting firm, to bolster and facilitate Sirona's business activities.
-
Sirona Biochem: Investing News Network Interview with CSO, Dr. Geraldine Deliencourt-GodefroyAn In-Depth Look at Anti-Aging Compound TFC-1326
5/11/2023
Sirona Biochem Corp. is pleased to announce that the Investing News Network has published an exclusive video interview with Dr. Geraldine Deliencourt-Godefroy, the Chief Scientific Officer of Sirona.
-
Sirona Biochem Announces Close of Oversubscribed Debenture Financing
4/20/2023
Sirona Biochem Corp. announced that it has closed an oversubscribed, non-brokered convertible debenture for gross proceeds of $1,563,600.
-
Sirona Biochem Announces Debenture Financing
3/23/2023
Sirona Biochem Corp. is pleased to announce a non-brokered private placement offering of unsecured, convertible debentures.
-
Sirona Biochem Receives Antiviral Testing Results
2/27/2023
Sirona Biochem Corp. is pleased to announce it has received results from its research collaboration with the International Centre for Genetic Engineering and Biotechnology to advance Sirona’s antiviral library of compounds.
-
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
1/16/2023
Sirona Biochem Corp. announces the termination of the Rodan + Fields agreement for supply and use of TFC-1067 in commercial formulations.